Master Relative Effectiveness Assessment - Training Course Brussels
16.03.20 - 16.03.20
The course will cover key concepts and provide an overview of methods used in the assessment and appraisal of pharmaceuticals during the pricing and reimbursement (funding) decision-making process.
Objectives
- Key principles, notions and stakeholders in pricing & reimbursement policy
- Role of health technology assessment (HTA) in pricing & reimbursement policy
- Main approaches to HTA Europe
- HTA in different EU countries
- Relative effectiveness assessment as a basis for reimbursement decision
- Similarities and differences between regulatory and HTA requirements in the assessment process
Targeted audience
The course is aimed at professionals with limited/no technical experience of HTA who may face market access challenges and opportunities on a daily basis. The course will be of interest to participants from the pharmaceuticalindustry working in the field of:
- Market Access
- Government and Public Affairs
- Health Economics & Outcome Research
- Patient Advocacy
- Drug Development
- Regulatory Affairs
- Marketing
- Medical Affairs
As the training will cover perspectives from different stakeholders, representatives from government agencies, payer organisations, health insurance companies as well as hospital managers, patient advocates, academia and non-profit organisations are encouraged to attend as well.